Neurosterix completes Phase 1 trial of NTX‑253 and plans Phase 2 for schizophrenia
Addex Therapeutics' spin‑out Neurosterix finished its Phase 1 clinical program for NTX‑253, a positive allosteric modulator of the muscarinic M4 receptor aimed at treating schizophrenia. The study, which enrolled healthy volunteers and stable patients, generated safety and pharmacokinetic data that support moving the drug into Phase 2. Addex retains a 20% equity stake in Neurosterix, which was created in April 2024 after raising $65 million in a Series A round backed by investors linked to Perceptive Advisors. The announcement was made on 8 October 2026.
Why it matters
The progression to Phase 2 indicates that NTX‑253 has cleared an early safety hurdle, potentially adding a novel schizophrenia therapy to the market pipeline. Addex’s 20% ownership means any future value creation from Neurosterix could positively affect Addex’s shareholders, as reflected by a 10.5% rise in pre‑market trading of ADXN.
Key facts
- 1Neurosterix completed Phase 1 clinical studies of NTX‑253 on 8 October 2026. tradingview.com
- 2Addex holds a 20% equity interest in Neurosterix. tradingview.com
- 3Neurosterix plans to advance NTX‑253 into Phase 2 trials for schizophrenia. tradingview.com
- 4Neurosterix was spun out in April 2024 after raising $65 million in a Series A financing supported by funds associated with Perceptive Advisors. finanznachrichten.de
- 5NTX‑253 is a positive allosteric modulator of the muscarinic M4 receptor. rttnews.com
- 6ADXN stock traded at $3.13 at the close of Wednesday’s session, down 0.32%, and was at $3.29 in pre‑market trading, up 10.50%. rttnews.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.